Literature DB >> 17210723

Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features.

Virginie Dangles-Marie1, Marc Pocard, Sophie Richon, Louis-Bastien Weiswald, Franck Assayag, Patrick Saulnier, Jean-Gabriel Judde, Jean-Louis Janneau, Nathalie Auger, Pierre Validire, Bernard Dutrillaux, Françoise Praz, Dominique Bellet, Marie-France Poupon.   

Abstract

Obtaining representative human colon cancer cell lines from fresh tumors is technically difficult. Using 32 tumor fragments from patients with colon cancer, the present study shows that prior xenograft leads to more efficient cell line establishment compared with direct establishment from fresh tumors (P < 0.05). From 26 tumor specimens, we successfully established 20 tumor xenografts in nude mice (77%); among 19 of these xenografts, 9 (47%) led to cell lines, including four from liver metastases. Only 3 of 31 tumor specimens (9.7%) grew immediately in vitro, and all were derived from primary tumors. To compare major phenotypic and genotypic characteristics of human colon cancer cell lines derived from the same tumor fragment using two protocols, the two pairs of cell lines obtained from 2 of 32 tumor fragments were extensively studied. They displayed similar morphology and were able to form compact spheroids. Chemosensitivity to 5-fluorouracil, CPT11, and L-OHP differed between cell lines obtained from patient tumors and those derived from xenografts. Matched cell lines shared a common core of karyotype alterations and distinctive additional chromosomal aberrations. Expression levels of genes selected for their role in oncogenesis evaluated by real-time quantitative PCR were found to be statistically correlated whatever the in vitro culture model used. In conclusion, xenotransplantation in mice of tumor fragments before establishment of cell lines enables generation of more novel human cancer cell lines for investigation of colon cancer cell biology, opening up the opportunity of reproducing the diversity of this disease.

Entities:  

Mesh:

Year:  2007        PMID: 17210723     DOI: 10.1158/0008-5472.CAN-06-0594

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  85 in total

Review 1.  Patient-Derived Xenograft Models in Breast Cancer Research.

Authors:  Deukchae Na; Hyeong-Gon Moon
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.

Authors:  John J Arcaroli; W M Tai; Ryan McWilliams; Stacey Bagby; Patrick J Blatchford; Marileila Varella-Garcia; Alicia Purkey; Kevin S Quackenbush; Eun-Kee Song; Todd M Pitts; Dexiang Gao; Chris Lieu; Martine McManus; Aik Choon Tan; Xianxian Zheng; Qin Zhang; Mark Ozeck; Peter Olson; Zhi-Qin Jiang; Scott Kopetz; Antonio Jimeno; Stephen Keysar; Gail Eckhardt; Wells A Messersmith
Journal:  Int J Cancer       Date:  2015-07-22       Impact factor: 7.396

3.  Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture.

Authors:  Kien Pham; Daniel Delitto; Andrea E Knowlton; Emily R Hartlage; Ricky Madhavan; David H Gonzalo; Ryan M Thomas; Kevin E Behrns; Thomas J George; Steven J Hughes; Shannon M Wallet; Chen Liu; Jose G Trevino
Journal:  Am J Pathol       Date:  2016-04-18       Impact factor: 4.307

Review 4.  Development of Preclinical Models to Understand and Treat Colorectal Cancer.

Authors:  Judith S Sebolt-Leopold
Journal:  Clin Colon Rectal Surg       Date:  2018-04-01

5.  Colon cancers carrying BRAF V600E and β-catenin T41A activating mutations are resistant to numerous common anticancer drugs.

Authors:  Guangzhong Xu; Kai Li; Nengwei Zhang; Bin Zhu; Guosheng Feng; Qing Fan
Journal:  Oncol Lett       Date:  2018-01-25       Impact factor: 2.967

6.  Imaging a functional tumorigenic biomarker in the transformed epithelium.

Authors:  Aaron M LeBeau; Minhee Lee; Stephanie T Murphy; Byron C Hann; Robert S Warren; Romelyn Delos Santos; John Kurhanewicz; Samir M Hanash; Henry F VanBrocklin; Charles S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

7.  In situ protein expression in tumour spheres: development of an immunostaining protocol for confocal microscopy.

Authors:  Louis-Bastien Weiswald; Jean-Marc Guinebretière; Sophie Richon; Dominique Bellet; Bruno Saubaméa; Virginie Dangles-Marie
Journal:  BMC Cancer       Date:  2010-03-22       Impact factor: 4.430

8.  Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.

Authors:  Nabil Amirouchene-Angelozzi; Fariba Nemati; David Gentien; André Nicolas; Amaury Dumont; Guillaume Carita; Jacques Camonis; Laurence Desjardins; Nathalie Cassoux; Sophie Piperno-Neumann; Pascale Mariani; Xavier Sastre; Didier Decaudin; Sergio Roman-Roman
Journal:  Mol Oncol       Date:  2014-06-13       Impact factor: 6.603

9.  A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro.

Authors:  Vincent C Daniel; Luigi Marchionni; Jared S Hierman; Jonathan T Rhodes; Wendy L Devereux; Charles M Rudin; Rex Yung; Giovanni Parmigiani; Marion Dorsch; Craig D Peacock; D Neil Watkins
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

10.  Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness.

Authors:  L-B Weiswald; S Richon; P Validire; M Briffod; R Lai-Kuen; F P Cordelières; F Bertrand; D Dargere; G Massonnet; E Marangoni; B Gayet; M Pocard; I Bieche; M-F Poupon; D Bellet; V Dangles-Marie
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.